onasemnogene abeparvovec-xioi
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Spinal Muscular Atrophy
Conditions
Spinal Muscular Atrophy
Trial Timeline
Apr 2, 2018 → Jun 15, 2021
NCT ID
NCT03505099About onasemnogene abeparvovec-xioi
onasemnogene abeparvovec-xioi is a phase 3 stage product being developed by Novartis for Spinal Muscular Atrophy. The current trial status is completed. This product is registered under clinical trial identifier NCT03505099. Target conditions include Spinal Muscular Atrophy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04042025 | Phase 3 | Active |
| NCT03837184 | Phase 3 | Completed |
| NCT03461289 | Phase 3 | Completed |
| NCT03505099 | Phase 3 | Completed |
| NCT03381729 | Phase 1 | Terminated |
| NCT03306277 | Phase 3 | Completed |
| NCT03421977 | Pre-clinical | Active |
Competing Products
20 competing products in Spinal Muscular Atrophy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SUN13837 injection + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg | Astellas Pharma | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 2 | 52 |
| Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells | Sun Pharmaceutical | Phase 1 | 33 |
| Elezanumab | AbbVie | Pre-clinical | 23 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 52 |
| Ropivacaine + Bupivacaine | AstraZeneca | Phase 3 | 77 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 1 | 33 |
| Zolgensma | Novartis | Pre-clinical | 23 |
| BVS857 + Placebo | Novartis | Phase 2 | 52 |
| AVXS-101 | Novartis | Phase 1 | 33 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| Onasemnogene Abeparvovec-brve | Novartis | Approved | 85 |
| Onasemnogene Abeparvovec-xioi | Novartis | Pre-clinical | 23 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| branaplam | Novartis | Phase 1/2 | 41 |
| Onasemnogene Abeparvovec-xioi | Novartis | Phase 3 | 77 |
| onasemnogene abeparvovec | Novartis | Phase 3 | 77 |
| Risdiplam | Roche | Phase 1 | 33 |
| ATI355 | Novartis | Phase 1 | 33 |